Evidence map›Paper›PMID 41538760›Full record

ArticleJCO precision oncology2026

Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma.

Adriana C Gamboa, Kever A Lewis, Laura R Prakash, Zhouxuan Li, Wei Qiao, Dan Zhao, Mark W Hurd, Mahmoud Yousef, Naruhiko Ikoma, Michael P Kim and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Adriana C GamboaDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5464-2178
Kever A LewisDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0009-5386-3022
Laura R PrakashDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1846-2361
Zhouxuan LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wei QiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-0922-0726
Dan ZhaoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7066-9058
Mark W HurdAhmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6102-4925
Mahmoud YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0007-2550-4837
Naruhiko IkomaDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael P KimDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8269-854X
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6010-5590
Jessica E MaxwellDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6035-7288
Matthew H G KatzDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-3870-6968
Rebecca A SnyderDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4355-2185

Funding

TRANSLATIONAL AND ANALYTICAL CHEMISTRY COREP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PETER W PISTERS · 1985 to 2026
$279.3M
TRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2M
NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009599
6 · The paper itself

Abstract

purposeThe incidence of young-onset pancreatic cancer (YO-PC) has risen over the past two decades, yet its molecular characteristics and long-term outcomes remain poorly defined.

methodsWe retrospectively evaluated patients with PC treated at a tertiary referral center from 2016 to 2022 who had available molecular data. Patients were classified as YO-PC (≤50 years) or average-onset PC (AO-PC, >50 years). A subset analysis examined outcomes in those who underwent curative-intent pancreatectomy. Primary end points included overall survival (OS) and recurrence-free survival (RFS).

resultsAmong 511 patients, 10.9% had YO-PC (n = 56; median age 44 years). Patients with YO-PC more commonly self-identified as non-White compared with patients with AO-PC (41.1%

conclusionIn this single-institution study, patients with YO-PC and AO-PC demonstrated similar clinicopathologic and molecular profiles; however, the study population to date may be underpowered. Routine molecular testing on all patients diagnosed with PC will be critical to better understand its clinical and molecular heterogeneity and to inform design of practice-changing clinical trials.

Indexed as

AdenocarcinomaPancreatic NeoplasmsAdultAge of OnsetFemaleHumansMaleMiddle AgedMutationProto-Oncogene Proteins p21(ras)Retrospective StudiesProto-Oncogene Proteins p21(ras)

Identifiers

PMID41538760
PMCPMC12810767

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.